Le Lézard
Classified in: Health, Science and technology
Subject: TDS

Intec Pharma to Participate in the Oppenheimer Specialty Pharma Summit



JERUSALEM, October 6, 2017 /PRNewswire/ --

Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in the Oppenheimer Specialty Pharma Summit to be held October 11, 2017 at the Sofitel Hotel in New York City.

Date:  Wednesday, October 11, 2017

Venue: Sofitel New York Hotel

Format:  One-on-One Meetings with Investors

Presenter: Jeffrey A. Meckler, Chief Executive Officer of Intec Pharma

The investor presentation will be posted to the Events section of the Company's website at http://www.intecpharma.com.  

About Intec Pharma Ltd. 

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC), which is being developed for various indications including low back neuropathic pain and fibromyalgia.

Contacts:
Jeffrey A. Meckler
Chief Executive Officer
Intec Pharma Ltd.
+1-646-374-8050
jeffrey@intecpharma.com  

SOURCE Intec Pharma Ltd.


These press releases may also interest you

at 20:30
HITLAB, in association with StartHealth, an initiative of Unitus Seed Fund and part of India's leading impact venture fund investing in early-stage startups innovating for the masses, today announced the 2018 HITLAB World Cup: India. Innovators...

at 20:18
CannaSOS is in the second stage of the Public Presale with its PerksCoin ICO and is making headway as 10,000,000 PCT tokens have already been sold in the first stage at a 40 percent discount. The PerksCoin ICO has been launched to address some of...

at 20:18
Physical Rehabilitation Network (PRN) announced the opening of a new facility in San Juan Capistrano under the California Rehabilitation and Sports Therapy (Cal Rehab) brand. This marks the company's 28th location in the Southern California market...

at 19:24
George Clinical, a leading full-service CRO in the US and Asia-Pacific region, is pleased to announce that Matthew Reabold, Sr. has been promoted to the Head of Business Development, USA. George Clinical, headquartered in Sydney, Australia,...

at 18:25
Paradigm is pleased to announce an upgrade to our offering. All Paradigm Cancer Diagnostic (PCDx) tests ordered for patients with lung cancer now also include 17 fusions, as well as EGFR and MET skipping events.  The fusions include: ALK, AXL, BRAF,...

at 18:15
RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased OSI Systems, Inc. ("OSI" or the "Company") securities between August 16, 2013 and December 5, 2017, inclusive (the "Class Period")....




News published on 6 october 2017 at 07:00 and distributed by: